AstraZeneca and Merck said the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending the use of Lynparza tablets, as monotherapy for adult patients with germline BRCA1/2-mutations, who have human epidermal growth factor receptor 2–negative locally advanced or metastatic breast cancer.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
